[go: up one dir, main page]

TR200002097A2 - Triazol ve imidazol türevleri - Google Patents

Triazol ve imidazol türevleri

Info

Publication number
TR200002097A2
TR200002097A2 TR2000/02097A TR200002097A TR200002097A2 TR 200002097 A2 TR200002097 A2 TR 200002097A2 TR 2000/02097 A TR2000/02097 A TR 2000/02097A TR 200002097 A TR200002097 A TR 200002097A TR 200002097 A2 TR200002097 A2 TR 200002097A2
Authority
TR
Turkey
Prior art keywords
triazole
imidazole derivatives
compounds
pharmaceutically acceptable
general formula
Prior art date
Application number
TR2000/02097A
Other languages
English (en)
Other versions
TR200002097A3 (tr
Inventor
Alanine Alexander
B�Ttelmann Bernd
Heitz Neidhart Mar�E-Paule
Jaeschke Georg
Pinard Emmanuel
Wyler Rene
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200002097A2 publication Critical patent/TR200002097A2/tr
Publication of TR200002097A3 publication Critical patent/TR200002097A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Mevcut bulus, asagidaki genel formülün bilesikleri ile ilgilidir: ve bunlarin farmasötik açidan kabul edilebilir asit ilave tuzlarini simgeler. Bu bilesikler, NMDA reseptör alt tipi selektif blokerleri ile iliskili hastaliklarin tedavisi için kullanilabilir.
TR2000/02097A 1999-07-21 2000-07-19 Triazol ve imidazol türevleri TR200002097A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99114313 1999-07-21

Publications (2)

Publication Number Publication Date
TR200002097A2 true TR200002097A2 (tr) 2001-02-21
TR200002097A3 TR200002097A3 (tr) 2001-02-21

Family

ID=8238635

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02097A TR200002097A3 (tr) 1999-07-21 2000-07-19 Triazol ve imidazol türevleri

Country Status (29)

Country Link
US (1) US6265426B1 (tr)
EP (1) EP1070708B1 (tr)
JP (1) JP3628946B2 (tr)
KR (1) KR100383776B1 (tr)
CN (1) CN1148357C (tr)
AR (1) AR024790A1 (tr)
AT (1) ATE257827T1 (tr)
AU (1) AU773463B2 (tr)
BR (1) BR0003075A (tr)
CA (1) CA2314009C (tr)
CO (1) CO5190713A1 (tr)
DE (1) DE60007697T2 (tr)
DK (1) DK1070708T3 (tr)
ES (1) ES2211420T3 (tr)
HR (1) HRP20000482A2 (tr)
HU (1) HUP0002792A3 (tr)
ID (1) ID26599A (tr)
IL (1) IL137328A0 (tr)
MA (1) MA26747A1 (tr)
MX (1) MXPA00007069A (tr)
NO (1) NO20003723L (tr)
NZ (1) NZ505766A (tr)
PE (1) PE20010349A1 (tr)
PL (1) PL341616A1 (tr)
PT (1) PT1070708E (tr)
SG (1) SG98422A1 (tr)
TR (1) TR200002097A3 (tr)
UY (1) UY26253A1 (tr)
ZA (1) ZA200003680B (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6610723B2 (en) * 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory PH VALVE DEPENDENT NMDA RECEPTOR ANTAGONISTS
US6951875B2 (en) 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
AU2003273096A1 (en) * 2002-10-22 2004-05-13 Korea Research Institute Of Chemical Technology Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
US7084145B2 (en) * 2002-10-25 2006-08-01 Pfizer Inc. Triazole compounds useful in therapy
US20040192743A1 (en) * 2003-02-12 2004-09-30 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US7790754B2 (en) * 2003-12-22 2010-09-07 Merck Sharp & Dohme Corp. Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
AU2005214349B2 (en) * 2004-02-12 2011-11-03 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
KR20080094806A (ko) * 2006-01-30 2008-10-24 트랜스테크 파르마, 인크. 치환된 이미다졸 유도체 및 이의 ＰＴＰａｓｅ 억제제로서의 용도
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
JP5523839B2 (ja) 2007-02-08 2014-06-18 シンタ ファーマシューティカルズ コーポレーション 癌などの増殖障害の治療に有用なトリアゾール化合物
EP2430921B1 (en) * 2007-04-03 2017-07-05 E. I. du Pont de Nemours and Company Substituted benzene fungicides
WO2008131148A1 (en) * 2007-04-19 2008-10-30 The Trustees Of The University Of Pennsylvania Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
JP2010532382A (ja) * 2007-06-29 2010-10-07 エモリー・ユニバーシテイ 神経保護のためのｎｍｄａ受容体拮抗薬
MX2010004177A (es) 2007-10-18 2010-05-03 Janssen Pharmaceutica Nv 1,2,4-triazoles trisustituidos.
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
ES2442932T3 (es) 2008-03-19 2014-02-14 Janssen Pharmaceutica N.V. 1,2,4-Triazoles trisustituidos como moduladores de receptores nicotínicos de acetilcolina
NZ588698A (en) * 2008-03-27 2012-06-29 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
CL2009001125A1 (es) 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
RU2532394C1 (ru) * 2013-10-29 2014-11-10 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") ПРИМЕНЕНИЕ БРОМИДА 1-β-ФЕНИЛЭТИЛ)-4-АМИНО-1,2,4-ТРИАЗОЛИЯ (ГИПЕРТРИЛ) КАК АКТИВНОЙ ОСНОВЫ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ КОРРЕКЦИИ НАРУШЕНИЙ ФУНКЦИОНИРОВАНИЯ НИТРОКСИДЕРГИЧЕСКОЙ СИСТЕМЫ ОРГАНОВ-МИШЕНЕЙ ПРИ ГОМОЦИСТЕИНЕМИИ И ОСТРЫХ НАРУШЕНИЯХ МОЗГОВОГО КРОВООБРАЩЕНИЯ
BR112017003918B1 (pt) * 2014-08-29 2022-05-03 Fmc Corporation Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
US12054464B1 (en) 2023-10-23 2024-08-06 King Faisal University Methyl 4-((5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzoate as an antimicrobial compound
US11912670B1 (en) 2023-10-25 2024-02-27 King Faisal University Ethyl 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoate as an antimicrobial compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579352A (en) * 1977-05-06 1980-11-19 Lepetit Spa 3,5-disubstituted-1h-1,2,4-triazoles
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JP2002515400A (ja) * 1997-07-03 2002-05-28 ニューロジェン・コーポレーション ある種のジアリールイミダゾール誘導体；新規なクラスのｎｐｙ特異的リガンド
IT1300055B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
JP2006512767A (ja) 2003-01-02 2006-04-13 ピー・デイ・エフ　ソリユーシヨンズ　インコーポレイテツド 歩留まり改善

Also Published As

Publication number Publication date
HRP20000482A2 (en) 2001-06-30
DE60007697T2 (de) 2004-12-09
CO5190713A1 (es) 2002-08-29
JP2001064263A (ja) 2001-03-13
ID26599A (id) 2001-01-25
PT1070708E (pt) 2004-05-31
PL341616A1 (en) 2001-01-29
NO20003723D0 (no) 2000-07-20
CA2314009C (en) 2008-09-30
DK1070708T3 (da) 2004-05-10
EP1070708A1 (en) 2001-01-24
CN1281852A (zh) 2001-01-31
NO20003723L (no) 2001-01-22
DE60007697D1 (de) 2004-02-19
PE20010349A1 (es) 2001-03-26
CN1148357C (zh) 2004-05-05
AU773463B2 (en) 2004-05-27
CA2314009A1 (en) 2001-01-21
HUP0002792A3 (en) 2002-10-28
ES2211420T3 (es) 2004-07-16
SG98422A1 (en) 2003-09-19
AU4865100A (en) 2001-01-25
KR20010049825A (ko) 2001-06-15
MA26747A1 (fr) 2004-12-20
HUP0002792A2 (hu) 2001-09-28
AR024790A1 (es) 2002-10-23
TR200002097A3 (tr) 2001-02-21
NZ505766A (en) 2002-03-28
IL137328A0 (en) 2001-07-24
MXPA00007069A (es) 2002-04-24
EP1070708B1 (en) 2004-01-14
BR0003075A (pt) 2001-03-13
US6265426B1 (en) 2001-07-24
KR100383776B1 (ko) 2003-05-12
ATE257827T1 (de) 2004-01-15
HU0002792D0 (en) 2000-09-28
UY26253A1 (es) 2000-10-31
JP3628946B2 (ja) 2005-03-16
ZA200003680B (en) 2001-01-22

Similar Documents

Publication Publication Date Title
TR200002097A2 (tr) Triazol ve imidazol türevleri
JO2503B1 (en) Benzathiazole derivatives
DE60037597D1 (de) Imidazol- Derivate
MX2007003329A (es) Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
TR200103607T2 (tr) Pürin Türevleri
MX2007003332A (es) Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
TR200201001T2 (tr) Pürin türevleri
ATE301651T1 (de) Substituierte benzimidazole
TR200000520A2 (tr) 4-Fenil-piridin türevleri.
ATE254110T1 (de) Antiproliferative imidazol wirkstoffe
BR9711342A (pt) Antagonistas de receptor de bombesina nÆo-pept¡do
TR200300766T2 (tr) A1 adenosin reseptörü antagonistleri olarak yoğunlaştırılmış purin türevleri.
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
MEP13308A (en) 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
IT1255802B (it) Derivati imidazolici ad attivita' a ii antagonista
NO20002655L (no) 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet
TR199500956A2 (tr) Benzimidazol türevleri.
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
HK1049486A1 (zh) 作為mcp-1受體拮抗劑的吲類衍生物
DE69828390D1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
BR0014145A (pt) Compostos de benzimidazol substituìdo por alcóxi, preparações farmacêuticas contendo o mesmo, e métodos de uso do mesmo
CA2421826A1 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
NO20031841L (no) Triazolderivater og farmasöytiske preparater inneholdende disse
NO883263D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater.
ATE256656T1 (de) Adamantancarboximidamid-derivate und ihre anwendung als nmda-antagonisten